June 16, 2016
Former CEO of Crescendo Bioscience Brings Three-Plus Decades of Experience in Healthcare Industry to San Diego-based Diagnostic Company.
December 28, 2015
CEO of Leading Diagnostics Innovator to Discuss Inflection Point for Industry and How New Technologies Can Transform Doctor, Patient Experience.
KCAS Bioanalytical & Biomarker Services and Genalyte Announce the Availability of GLP-compliant Assays on the Maverick™ Detection System
October 7, 2015
KCAS Bioanalytical & Biomarker Services, a small and large molecule Good Laboratory Practices (GLP)-compliant bioanalytical and biomarker Contract Research Organization (CRO), and Genalyte, Inc., a next-generation clinical and diagnostic life science detection company, announced today a collaborative agreement for KCAS to provide services using Genalyte’s multiplexed Maverick™ Detection System.
August 18, 2015
Genalyte, Inc. announced today it has completed a Series C Financing round of $44 million, led by Khosla Ventures. The company is redefining diagnostics with a testing platform and microchip technology that can be utilized in physician offices. With the application of a single drop of blood to a silicon microchip, Genalyte’s Maverick Detection System can offer a complete panel of diagnostic test results in fifteen minutes.
February 3, 2015
Having completed the first phase of a $1 million National Cancer Institute grant to develop a panel of tumor-associated antibodies (TAAs) to help detect cancer and assess patient response to immune-modulating cancer drugs, Genalyte is now gearing up to manufacture a set of chips covering this panel to support the second phase of the project.
February 2, 2015
Genalyte, Inc. today announced it has hired Todd Ritter, a former Defense Department Senior Medical Advisor and former Chief of Corporate Development at BioFire Diagnostics, Inc., as their new Vice President of Corporate Development. Ritter joins the company effective immediately.
January 28, 2015
M.D. Anderson, Providence Cancer Center, and Wayne State University install new technology and testing platform for cancer screening. San Diego-based biotechnology company Genalyte announced today the completion of Phase 1 of its $1 million National Cancer Institute (NCI) grant, successfully developing and deploying a cancer biomarker panel and testing platform for screening.
Genalyte Expands into Cancer Profiling with $1 Million NCI Grant to Develop Cancer Biomarker Panel; Establishes Collaborations with Three Cancer Research Centers
October 18, 2013
Genalyte and Barbara Davis Diabetes Center Collaborate to Advance Multiplexed Antigen Panel for Early Diagnosis of Type 1 Diabetes
August 15, 2013
Genalyte Streamlines Immunogenicity Testing with Launch of MT-ADA Assay for Real-Time Detection of Anti-Drug Antibodies
April 3, 2013
Genalyte Announces CE Mark for Maverick TM Detection System and Signs On First European Distributors
March 26, 2013
Genalyte Awarded $500,000 SBIR Grant to Develop Multiplexed Assays for Early Detection and Monitoring of Type 1 Diabetes
December 11, 2012
September 24, 2012
Genalyte Teams with Scienion to Provide sciFLEXARRAYER Dispensers for its Maverick™ Detection Platform and Launches Custom Chip Spotting Service
September 19, 2012
July 24, 2012
Genalyte To Launch Early Access Program For Maverick™ Next-Generation Multiplexing Platform at Upcoming Immunology Conference
May 1, 2012